Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.

PR Newswire December 19, 2019

Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

PR Newswire November 15, 2019

Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

PR Newswire November 14, 2019

Jazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting

PR Newswire November 7, 2019

Jazz Pharmaceuticals Announces Third Quarter 2019 Financial Results

PR Newswire November 5, 2019

Jazz Pharmaceuticals to Report 2019 Third Quarter Financial Results on November 5, 2019

PR Newswire October 22, 2019

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity

PR Newswire October 10, 2019

Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans

PR Newswire September 30, 2019

Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019

PR Newswire September 25, 2019

Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update

PR Newswire September 18, 2019

Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

PR Newswire August 27, 2019

Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.

PR Newswire August 12, 2019

Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results

PR Newswire August 6, 2019

Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program

PR Newswire August 6, 2019

Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019

PR Newswire July 23, 2019

Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma

PR Newswire July 10, 2019

Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update

PR Newswire June 25, 2019

Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi(TM) (solriamfetol)

PR Newswire June 17, 2019

Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development

PR Newswire June 3, 2019

Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

PR Newswire May 16, 2019